Supplementary Online Content

Zissimopoulos JM, Barthold D, Brinton RD, Joyce G. Sex and race differences in the association between statin use and incidence of Alzheimer disease. *JAMA Neurol.* doi:10.1001/jamaneurol.2016.3783

eTable 1. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Exposure to Statins in 2006-2008, Relative to Those With No Use 2006-2012

eTable 2. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Individuals Observed 2006-2013

eTable 3. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Users in 50th Percentile or Higher

eTable 4. Hazard Ratios (With *P* values) of AD Incidence in Years 2012-2013 Only, Associated With High Statin Exposure in 2006-2008, Relative to Low Exposure

eTable 5. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure for Different Thresholds Defining High Statin Exposure, Relative to Low Exposures

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2016 American Medical Association. All rights reserved.

			,						
		Fer	nale		Male				
	All	White	Hispan	Black	All	White	Hispan	Black	
			ic				ic		
All	0.793	0.789	0.821	0.817	0.786	0.777	0.870	0.806	
	p<0.00	p<0.00	p<0.00	p<0.00	p<0.00	p<0.00	p=0.08	p=0.01	
	1	1	1	1	1	1	6	5	
Simvastati	0.800	0.801	0.827	0.769	0.812	0.797	0.879	0.887	
n									
	p<0.00	p<0.00	p<0.00	p<0.00	p<0.00	p<0.00	p=0.23	p=0.30	
	1	1	1	1	1	1	0	3	
Atorvastati	0.788	0.784	0.792	0.863	0.780	0.773	0.836	0.816	
n									
	p<0.00	p<0.00	p=0.00	p=0.04	p<0.00	p<0.00	p=0.15	p=0.14	
	1	1	3	3	1	1	0	6	
Pravastati	0.753	0.745	0.746	0.911	0.741	0.744	0.639	0.862	
n									
	p<0.00	p<0.00	p=0.10	p=0.57	p<0.00	p=0.00	p=0.21	p=0.64	
	1	1	3	3	1	1	2	4	
Rosuvastat	0.770	0.723	1.024	0.796	0.693	0.630	1.162	1.008	
in									
	p<0.00	p<0.00	p=0.86	p=0.22	p<0.00	p<0.00	p=0.50	p=0.98	
	- 1	- 1	2	5	- 1	1	3	0	

eTable 1: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Exposure to Statins in 2006-2008, Relative to Those With No Use 2006-2012

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with any exposure to statins, compared to no exposure. Individuals with high statin exposure are those with at least two days of filled prescriptions in the 50th percentile or higher of days of use per year in at least 1 of the 3 years from 2006 to 2008. The comparison groups did not use statins from 2006 to 2012.

		Fer	nale		Male				
	All	White	Hispan	Black	All	White	Hispan	Black	
			ic				ic		
All	0.863	0.867	0.928	0.817	0.840	0.839	0.681	0.958	
	p<0.00	p<0.00	p=0.32	p=0.00	p<0.00	p<0.00	p=0.00	p=0.75	
	1	1	7	4	1	1	3	7	
Simvastati	0.864	0.871	0.870	0.809	0.868	0.896	0.723	0.801	
n									
	p<0.00	p<0.00	p=0.21	p=0.04	p=0.00	p=0.05	p=0.07	p=0.30	
	1	1	0	7	7	9	3	7	
Atorvastati	0.825	0.836	0.874	0.842	0.820	0.815	0.676	0.867	
n									
	p<0.00	p<0.00	p=0.30	p=0.13	p<0.00	p=0.00	p=0.07	p=0.52	
	1	1	7	4	1	1	1	1	
Pravastati	0.835	0.797	0.963	0.892	0.782	0.821	0.628	0.751	
n									
	p=0.03	p=0.01	p=0.89	p=0.71	p=0.05	p=0.15	p=0.38	p=0.64	
	2	6	3	3	7	7	6	2	
Rosuvastat	0.901	0.900	1.393	0.654	0.805	0.821	0.476	2.740	
in									
	p=0.26	p=0.33	p=0.16	p=0.27	p=0.17	p=0.27	p=0.21	p=0.11	
	3	3	7	3	9	4	8	8	

eTable 2: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Individuals Observed 2006-2013

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with high exposure to statins, compared to low exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 50th percentile or higher of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the designated statin, but for fewer days, or later in the sample period.

	Female				Male				
	All	White	Hispan Black		All	White	Hispan	Black	
			ic				ic		
All	0.834	0.847	0.803	0.773	0.877	0.892	0.680	0.857	
	p<0.00	p<0.00	p=0.00	p<0.00	p<0.00	p=0.00	p=0.00	p=0.20	
	1	1	2	1	1	1	1	1	
Simvastati	0.836	0.860	0.724	0.771	0.898	0.921	0.731	0.748	
n									
	p<0.00	p<0.00	p=0.00	p=0.00	p=0.01	p=0.11	p=0.05	p=0.10	
	1	1	2	5	9	1	3	3	
Atorvastati	0.835	0.876	0.629	0.739	0.969	0.968	0.682	1.080	
n									
	p<0.00	p=0.00	p=0.00	p=0.01	p=0.59	p=0.62	p=0.11	p=0.75	
	1	2	2	0	9	5	0	9	
Pravastati	0.882	0.888	0.841	0.666	0.803	0.856	0.672	0.707	
n									
	p=0.10	p=0.16	p=0.55	p=0.17	p=0.06	p=0.22	p=0.42	p=0.53	
	1	0	2	1	5	4	4	1	
Rosuvastat	0.850	0.837	1.053	0.649	0.900	0.882	0.847	2.319	
in									
	p=0.06	p=0.08	p=0.81	p=0.20	p=0.44	p=0.42	p=0.65	p=0.22	
	7	7	6	3	6	7	8	7	

eTable 3: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Users in 50th Percentile or Higher

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with high exposure to statins, compared to low exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 50th percentile of higher of days of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the same quantity of the same statin, in 2009, 2010, 2011, or 2012.

	Female	Male
	All	All
All	0.866	0.901
	p<0.001	p=0.037
Simvastatin	0.893	0.907
	p=0.023	p=0.191
Atorvastatin	0.810	0.949
	p<0.001	p=0.494
Pravastatin	0.720	0.804
	p=0.013	p=0.238
Rosuvastatin	0.754	0.636
	p=0.055	p=0.103

eTable 4: Hazard Ratios (With *P* Values) of AD Incidence in Years 2012-2013 Only, Associated With High Statin Exposure in 2006-2008, Relative to Low Exposure

Hazard ratios, depicting relative risk of AD incidence during 2012-2013 for those with high exposure to statins, compared to low exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 50th percentile or higher of days of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the designated statin, but for fewer days, or later in the sample period. Sample restricted to those observed 2006-2012.

		Fer	nale		Male				
	All	White	Hispani	Black	All	White	Hispani	Black	
			с				с		
All									
Statins									
25th %	0.896	0.911	0.942	0.786	0.897	0.902	0.884	0.856	
	p<0.00	p<0.00	p=0.316	p=0.70	p<0.00	p=0.00	p=0.188	p=0.13	
	1	1		8	1	2		6	
50th %	0.854	0.856			0.875				
	p<0.00	p<0.00	p=0.059	p<0.00	p<0.00	p<0.00	p=0.001	p=0.17	
	1	1		1	1	1		6	
75th %	0.830	0.832	0.886		0.805	0.825			
	p<0.00	p<0.00	p=0.128	p=0.00	p<0.00	p<0.00	p<0.001	p=0.13	
~	1	1		1	1	1		4	
Simvastati									
25th %	0.873		0.886	0.794	0.893	0.901	0.811	0.866	
	p<0.00	p<0.00	p=0.103	1	p=0.00	p=0.01	p=0.061	p=0.27	
	1	1	0.000	1	2	3	0.470	0	
50th %	0.850	0.862	0.820		0.867	0.896		0.768	
	p<0.00	p<0.00	p=0.043	p=0.00	p=0.00	p=0.02	p=0.009	p=0.12	
	1	1	0.500	5	1	4	0.505	2	
75th %	0.825	0.839		0.747	0.807	0.831			
	p<0.00	p<0.00	p=0.066	p=0.00	p<0.00	p=0.00	p=0.001	p=0.22	
• • • • •	1	1		8	1	1		1	
Atorvastat		0.000	0.000	0.000	0.000	0.016	0.016	0.000	
25th %	0.890				0.936				
	p<0.00	p=0.00	p=0.474	p=0.11	p=0.12	p=0.25	p=0.237	p=0.49	
50(1.0/	1	1	0.750	9	7	8	0 (12	<u> </u>	
50th %	0.824	0.835			0.901				
	p<0.00	p<0.00	p=0.024	p=0.03 0	p=0.02	-	p=0.009	p=0.64	
75th 0/	0 704	0.807	0.724	•	4	3	0.462	0 852	
75th %	0.794 p<0.00	0.807 p<0.00	0.724 p=0.028	0.798 p=0.05	0.821 p<0.00	0.862 p=0.01	0.462 p=0.002	0.852 p=0.48	
	p<0.00 1	p<0.00	p=0.028	p=0.03 5	p<0.00	p=0.01 0	p=0.002	p=0.48 1	
Pravastati		1		5	1	0		1	
25th %	0.862	0.860	0.919	0.868	0.875	0.900	0.905	0.804	
43tH /0	p=0.01	p=0.02	0.919 p=0.677	p=0.47	p=0.14	p=0.29	0.903 p=0.785	p=0.56	
	p=0.01 1	p=0.02	P-0.077	p=0.47 9	p=0.14 6	p=0.29	P-0.703	p=0.30 9	
50th %	0.821	0.816	0.818	0.756	0.779	0.823	0.748	0.702	
JUH /0	p=0.00	p=0.01	p=0.460	p=0.32	p=0.02	p=0.10	p=0.539	p=0.49	
	р=0.00 б	p=0.01 1	P-0.400	p=0.32 7	p=0.02 6	р=0.10 б	P-0.559	p=0.49 8	
75th %	0.783	0.772	0.940	0.710	0.683	0.720	0.683	0.543	
/Jul /0	0.765	0.772	0.240	0.710	0.005	0.720	0.005	0.545	

eTable 5: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure for Different Thresholds Defining High Statin Exposure, Relative to Low Exposures

© 2016 American Medical Association. All rights reserved.

	p=0.00	p=0.00	p=0.845	p=0.37	p=0.00	p=0.02	p=0.528	p=0.40
	5	7		3	5	3		0
Rosuvasta	tin							
25th %	0.921	0.934	0.950	0.790	0.852	0.851	0.821	1.149
	p=0.16	p=0.33	p=0.736	p=0.24	p=0.10	p=0.15	p=0.444	p=0.73
	7	0		3	2	8		9
50th %	0.828	0.810	1.172	0.671	0.898	0.879	0.998	1.530
	p=0.02	p=0.03	p=0.440	p=0.21	p=0.40	p=0.38	p=0.996	p=0.42
	3	1		7	4	1		3
75th %	0.757	0.762	1.146	0.337	0.827	0.840	1.081	1.134
	p=0.00	p=0.02	p=0.623	p=0.06	p=0.23	p=0.32	p=0.858	p=0.86
	9	5		2	3	7		4

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with the designated exposure to statins, compared to lower exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 25th, 50th, or 75th percentile of higher of days of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the designated statin, but for fewer days, or later in the sample period.